Annual Financial Assessment European Medicines Agency

The European Medicine Agency (EMA) has established ‘eligibility criteria’ in order to make sure that it only establishes dialogue with the most suitable organisations that act in the interests of European patients, consumers and healthcare professionals. The European Association of Urology would like to engage in dialogue with the EMA and has provided the following information for the evaluation of eligibility.

As part of the evaluation for eligibility, the European Association of Urology has provided the following financial information to by assessed by the parameters as set by the European Medicine Agency:

  • Royalties EAU scientific journal: 11%, 50% non-industry – 50% industry
  • Results EAU meetings: 78%, 40% non-industry, 60% industry
  • Membership fees: 6%, 100% non-industry
  • Educational grants: 4%, 100% industry
  • Other educational products and services: 1%, 100% non-industry

Funding Resources:
The following pharmaceutical companies provide funding to EAU:

  • Allergan
  • Astellas
  • Boston Scientific
  • Bristol-Myers Squibb
  • Ferring Pharmaceuticals
  • GlaxoSmithKline
  • Ipsen
  • Janssen Pharmaceutica
  • Pierre Fabre Médicament
  • Sanofi Genzyme

The highest contribution from a single company is less than 5% of the organisation’s total income.

Code of Ethics
In order to ensure good governance, interactions should be based on fundamental principles of integrity, mutual respect, responsiveness, accountability, collaboration and transparency. The EAU Code of Ethics set standards for industry partners with regard to ethical interactions with the healthcare community. In order to make funding partnerships work in practice, to ensure the integrity of both the funder and EAU is maintained, and to demonstrate to other stakeholders that our relationships are absolutely scrupulous, the following key principles underpin our acceptance of funding.

Code of Ethics by European Association of Urology

EMA 2015 annual report